Get the Stockscreener App
6.54
10.90%
-0.80
After Hours:
6.51
-0.03
-0.46%
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc Stock (BHC) Latest News
Bausch & Lomb drops after ending sales process - MSN
Jefferies cuts Bausch Health stock rating to hold, target to $8 - MSN
Bausch Health cut to hold by Jefferies over B+L update (BHC:NYSE) - Seeking Alpha
Bausch Health Companies Inc. - Baystreet.ca
Bausch + Lomb won’t sell after engaging with potential buyers - Mass Device
Bausch + Lomb ends sale process, to focus on 2025 plans - MSN
Contact lens maker Bausch + Lomb rules out going private at this time - Yahoo Canada Finance
Bausch Health Retains Bausch + Lomb, Explores New Financial Strategies - TipRanks
Bausch + Lomb Sinks After Disclosing It Won’t Go Private Now - Yahoo Finance Australia
Bausch + Lomb sinks after disclosing it won’t go private now - The Malaysian Reserve
Contact lens maker Bausch + Lomb rules out take-private deal -February 06, 2025 at 07:27 am EST - Marketscreener.com
Bausch Health Provides Update on Strategic Alternatives - ACCESS Newswire
Private Equity Buyout Rejected: Inside Bausch Health's Strategic Decision on Bausch + Lomb - StockTitan
Bausch + Lomb Privatization Deal Falls Through: Revenue Growth Still on Track - StockTitan
Private Management Group Inc. Cuts Position in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Keratoconus Treatment Market reached US$ 0.5 billion in 2022 - openPR
Oral Mucositis Market Growth with Trends, Analysis by Regions, - openPR
Proton Pump Inhibitors (PPIs) Market to Grow by USD 819.5 Million (2025-2029) with Drug Reformulation Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
Royal Bank of Canada Issues Pessimistic Forecast for Bausch Health Companies (NYSE:BHC) Stock Price - MarketBeat
Bausch Health Companies (NYSE:BHC) Shares Down 5.2%What's Next? - MarketBeat
BofA Adjusts Price Target on Bausch Health Companies to $7 From $6 -February 03, 2025 at 10:25 am EST - Marketscreener.com
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Rising Allergy Prevalence Boosts Growth, with AI Powering Market EvolutionTechnavio - Yahoo Finance
RBC Previews Bausch Health Q4 -January 30, 2025 at 12:41 pm EST - Marketscreener.com
Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch + Lomb, RBC Says - Marketscreener.com
Posterior Segment Eye Disorders Market Overall Study Report - openPR
Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch Health, Hoya, Johnson & Johnson, STAAR Surgical Co, Carl Zeiss Meditec, and Novartis - GlobeNewswire
Merit Financial Group LLC Makes New $228,000 Investment in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration - ACCESS Newswire
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock - MSN
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 - ACCESS Newswire
Bausch Health Companies (BHC) Stock Forecast and Price Target 2025 - MarketBeat
Zacks Research Brokers Lower Earnings Estimates for TSE:BHC - Defense World
Research Analysts Issue Forecasts for BHC FY2025 Earnings - Defense World
Stocks In Play: Bausch Health Companies Inc. By Baystreet.ca - Investing.com Canada
What is Zacks Research's Forecast for BHC FY2025 Earnings? - MarketBeat
Zacks Research Has Negative View of TSE:BHC FY2025 Earnings - MarketBeat
SG Americas Securities LLC Boosts Stake in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Bausch Health Announces Q4 2024 Earnings Call Date, Full Year Results Coming February 19 - StockTitan
Shareholders in Bausch Health Companies (NYSE:BHC) are in the red if they invested five years ago - Simply Wall St
Zacks Research Issues Positive Estimate for BHC Earnings - Defense World
Bausch Health Swaps Out Advisers After Years of Debt, Sale Talks - BNN Bloomberg
Nanotechnology Drug Delivery Market Expected To Reach USD - GlobeNewswire
Nanotechnology Drug Delivery Market Expected To Reach USD 213.2 Billion by 2032, with a CAGR of 9.3% | AstraZeneca, Sanofi, Bausch Health Companies Inc. - Yahoo Finance
Zacks Research Has Positive Forecast for BHC Q1 Earnings - MarketBeat
What is Zacks Research's Estimate for TSE:BHC Q1 Earnings? - MarketBeat
International team acts for Bausch Health Companies Inc. in a US$2bn cross-border senior notes financing - Norton Rose Fulbright
Intraocular Lens Market Detailed In New Research Report 2025 | - openPR
Xifaxan selected for CMS drug price talks in 2027 - MSN
Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) PT at $7.75 - Defense World
Bausch Health Companies (NYSE:BHC) Sees Strong Trading VolumeHere's Why - MarketBeat
Xifaxan selected for CMS drug price talks in 2027 By Investing.com - Investing.com Nigeria
Bausch Health acknowledges XIFAXAN selection for Medicare Negotiation Program - MSN
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Statement on Selection of XIFAXAN(R)?(rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - WICZ
Bausch Health’s XIFAXAN Selected for Medicare Price Negotiation - TipRanks
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - Yahoo Finance
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):